secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001104659-21-133637
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q3 net loss $33.8M; rusfertide hold lifted, PN-235 advancing to Phase 2
--------------------------------------------------------------------------------

- Net loss $33.8M ($0.70/share) vs $7.8M loss in Q3 2020; revenue $10.3M (incl. $8M catch-up from Janssen amendment).
- Cash $352.5M; expects to fund operations through 2024.
- FDA removed clinical hold on rusfertide; Phase 3 in PV planned Q1 2022; Zealand agreement cut future milestones/royalties by 50%.
- PN-943 Phase 2 IDEAL study enrollment steady; topline data from 12-week induction expected Q2 2022.
- IL-23: PN-235 Phase 2 psoriasis starts early 2022; $7.5M milestone from Janssen; up to ~$900M in potential milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465921133637/0001104659-21-133637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465921133637/tm2131730d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-133637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer